OMO.I. Mitrokhina

O.I. Mitrokhina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O.I. Mitrokhina has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effect of metabolic syndrome on the frequency and outcome of malignant neoplasms

    by O.I. Mitrokhina, M.I. Sekacheva, M.A. Osadchuk, I.N. Vasileva

    Objective. To assess the likelihood of developing malignant neoplasms, the features of their course and the five-year outcome, depending on the dynamics of anthropometric and biochemical parameters in patients with metabolic syndrome (MS). Material and methods. In a retrospective cohort study, data from 1993 patients were analyzed, of which 994 patients with MS formed the main group, 999 patients without MS — the comparison group. MS was determined by the presence of abdominal obesity (AO) in combination with two or more additional signs (dyslipidemia, hyperglycemia, arterial hypertension). The course and outcome of the disease in cancer patients with MS were considered depending on the dynamics of MS indicators one year and five years after the diagnosis was confirmed. Statistical analysis was performed using the SPSS INC 27.0 program. Results. In patients with MS, cases of malignant neoplasms were noted in 18.6% of patients, while in the absence of MS — only 7.3%. In an intergroup comparison, these differences reached the criteria of statistical significance (p<0.05). Normalization of biochemical parameters such as HDL, TG, and glucose levels one year and five years after cancer diagnosis reduces the risk of metastasis and recurrence and reduces the risk of death (p<0.05). On the contrary, an increase in the deviation from the norm leads to a progression of the process and increases the frequency of deaths. Conclusion. MS and its components are risk factors for cancer of any localization. With the normalization of previously identified changes that meet additional criteria for MS, a year after the identified oncopathology, the risk of metastasis and recurrence of the process decreases, and after five years, the risk of mortality from cancer decreases.

  • Metabolic syndrome as a risk factor for oncogenesis

    by M.A. Osadchuk, I.N. Vasilieva, V.V. Kozlov, O.I. Mitrokhina

    Metabolic syndrome (MS) is a risk factor for cardiovascular diseases and cancer, although the complete relationship between MS and cancer remains a problem far from being resolved. Hormonal and inflammatory changes in adipose tissue were reported to be associated with cancer. Objective. To study the probability of cancer development in patients with MS. Material and methods. An observational retrospective study including 994 patients (289 males and 705 females) was carried out at the outpatient center of Moscow (Diagnostic Center No. 5 of the Moscow Healthcare Department). The mean age of study patients was 62.48±13.49 years (20 to 87 years). The incidence of cancer and oncogenesis factors in patients with MS over 10 years and the association between its components (abdominal obesity, arterial hypertension, hyperglycemia, and hypertriglyceridemia) were analyzed. Odds ratios of carcinogenesis and 95% confidence intervals were estimated using the cross tables method. Results. Cancer onset was observed in every fifth patient with an MS duration of 13.5±2.41 years. Abdominal obesity was associated with an increased risk of various cancers. The most significant risk was associated with grade I obesity, metabolic disorders, and the age of patients. In addition, a retrospective analysis of data from MS patients revealed a protective effect of oral antidiabetic and hypolipidemic agents on cancer risk and mortality, although the mechanisms are not fully understood. Conclusions. Metabolic syndrome is a risk factor for cardiovascular diseases and cancer. Cardiovascular diseases, particularly arterial hypertension, increase the risk of cancer several-fold. Hyperglycemia also increases the risk of malignant neoplasms. Dyslipidemia has no effect on cancer development; however, more detailed studies with a larger sample are needed.